MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells
about
Intracellular Targeting of the Oncogenic MUC1-C Protein with a Novel GO-203 Nanoparticle FormulationOrigin of anti-tumor activity of the cysteine-containing GO peptides and further optimization of their cytotoxic properties.MUC1-C activates BMI1 in human cancer cells.MUC1-C Induces the LIN28B→LET-7→HMGA2 Axis to Regulate Self-Renewal in NSCLCING5 inhibits cancer aggressiveness via preventing EMT and is a potential prognostic biomarker for lung cancer.OCF can repress tumor metastasis by inhibiting epithelial-mesenchymal transition involved in PTEN/PI3K/AKT pathway in lung cancer cells.Mucin 1-mediated chemo-resistance in lung cancer cells.Inhibition of MUC1-C Suppresses MYC Expression and Attenuates Malignant Growth in KRAS Mutant Lung Adenocarcinomas.MUC1 upregulation promotes immune resistance in tumor cells undergoing brachyury-mediated epithelial-mesenchymal transition.Targeting MUC1-C inhibits the AKT-S6K1-elF4A pathway regulating TIGAR translation in colorectal cancer.Role of integrin-linked kinase in regulating the protein stability of the MUC1-C oncoprotein in pancreatic cancer cells.The aspirin metabolite salicylate inhibits lysine acetyltransferases and MUC1 induced epithelial to mesenchymal transition.MUC1-C Represses the Crumbs Complex Polarity Factor CRB3 and Downregulates the Hippo Pathway.Aptamer-hybrid nanoparticle bioconjugate efficiently delivers miRNA-29b to non-small-cell lung cancer cells and inhibits growth by downregulating essential oncoproteins.MUC1-C Oncoprotein Integrates a Program of EMT, Epigenetic Reprogramming and Immune Evasion in Human Carcinomas.MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer.ING5 knockdown enhances migration and invasion of lung cancer cells by inducing EMT via EGFR/PI3K/Akt and IL-6/STAT3 signaling pathways.Oncogene KRAS activates fatty acid synthase, resulting in specific ERK and lipid signatures associated with lung adenocarcinoma.MicroRNA-128 suppresses paclitaxel-resistant lung cancer by inhibiting MUC1-C and BMI-1 in cancer stem cells.Melorheostosis: Exome sequencing of an associated dermatosis implicates postzygotic mosaicism of mutated KRAS.Src promotes EGF-induced epithelial-to-mesenchymal transition and migration in gastric cancer cells by upregulating ZEB1 and ZEB2 through AKT.MicroRNA-148b inhibits proliferation and the epithelial-mesenchymal transition and increases radiosensitivity in non-small cell lung carcinomas by regulating ROCK1.Isoform-selective activity-based profiling of ERK signaling
P2860
Q28394194-EA87989D-193A-44FC-9C61-CC2E1521A398Q29248355-38D1E397-DB85-4A5D-8B7D-CE327056D3ABQ33704573-007DB5AA-C6D5-4019-8297-8E891C72F39BQ35204592-E2129B02-CA4F-4EB2-A2E0-4CD7CFAB0D35Q36140775-20FFD450-1AA5-402E-8F79-79A81CBCA9DDQ36310903-69C12BA1-DC5F-454E-84A8-62767775F418Q36507586-5E5A0713-2F1A-4C17-B6FB-392433E10FE5Q36693297-FBE238DE-2F82-459C-A50C-E095E5DF78A7Q36821095-6476CACB-36D1-4A2B-8489-90103AB023FDQ37622949-22A31A70-824F-4C7D-9AB5-24477B8F31C3Q38686618-A2C92263-2CB4-4D99-B5EE-8BAB11D34A41Q38697027-DF3F68AE-CF8F-4E22-9E86-77F2C220D59CQ38744303-5D0DE437-59BD-4CFB-9729-71DCA7F6C566Q38750446-065C116A-D283-4C6F-BC8A-EB5B1A6EE1A2Q39182659-B56EC9F3-0F24-4BC4-B3F6-399F56241E24Q41008660-2A4329E0-3F8D-4D5C-830E-8887A4EDC1C7Q41552636-8F5E0C93-F662-4939-8F9C-FCACA45A94ACQ43100869-86A973B3-410E-4C59-973B-FC69DA489139Q47202039-D875491B-90DD-43F6-B3BF-606FBF77EF26Q47566212-4BED6421-81D2-4DB5-BD64-FB1114E1ECD2Q47625476-76B30988-0493-4379-BC44-7491D0FE52D1Q52726212-26477B47-3E93-48AD-93C1-DCAC272BD068Q54964710-BB86AE52-9827-4345-8346-6C61878A27AF
P2860
MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells
@ast
MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells
@en
MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells
@nl
type
label
MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells
@ast
MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells
@en
MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells
@nl
prefLabel
MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells
@ast
MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells
@en
MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells
@nl
P2093
P2860
P356
P1433
P1476
MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells
@en
P2093
Akriti Kharbanda
Caining Jin
Donald Kufe
Hasan Rajabi
Maroof Alam
P2860
P304
P356
10.18632/ONCOTARGET.2360
P407
P577
2014-10-01T00:00:00Z